Beyond Restenosis
- 7 September 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 110 (10), 1226-1230
- https://doi.org/10.1161/01.cir.0000140721.27004.4b
Abstract
Background— In the first year after coronary stent implantation, clinical failures are driven mainly by procedural complications and restenosis, but the subsequent relative contributions of restenosis and disease progression to late failures are less clear. Methods and Results— We observed 1228 patients for 5 years after the implantation of stents as part of pivotal second-generation coronary stent trials. Clinical events of death, myocardial infarction, repeat revascularization, and repeat hospitalization for acute coronary syndrome or congestive heart failure were attributed to the index stented (target) lesion or other distinct sites (either in the target or other coronary vessels) and further classified as procedural, restenosis, or nonrestenosis. During the first year the hazard rate was 18.3% for target-lesion events and 12.4% for events unrelated to the target lesion. After the first year the average annual hazard rate was 1.7% for target-lesion events and 6.3% for nontarget-lesion events. By the fifth year, restenosis events occurred in 20.3% of patients, whereas 30-day procedural complications or later nonrestenosis events occurred in 37.9%, including 11.4% who also experienced a restenosis event, for a combined cumulative event rate of 46.4%. Diabetes mellitus and multivessel disease were independently associated with increased risk for both restenosis and nonrestenosis events. Conclusion— In a low-risk clinical trial population, the clinical outcome beyond 1 year after stenting is determined by a high rate of events related to disease progression in segments other than the stented lesion, which itself remains relatively stable.Keywords
This publication has 13 references indexed in Scilit:
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryThe New England Journal of Medicine, 2003
- Clinical restenosis after coronary stenting: perspectives from multicenter clinical trialsJournal of the American College of Cardiology, 2002
- Emergency Coronary Artery Bypass Surgery in the Contemporary Percutaneous Coronary Intervention EraCirculation, 2002
- Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary ArteriesCirculation, 2002
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationThe New England Journal of Medicine, 2002
- Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trialJournal of the American College of Cardiology, 2001
- Asymmetrical effects of angiographically assessed collateral flow on vasodilator and exercise stress-induced ischemiaJournal of the American College of Cardiology, 1998
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Predictive Factors of Restenosis After Coronary Stent PlacementJournal of the American College of Cardiology, 1997
- Long-Term (4- to 6-Year) Outcome of Palmaz-Schatz Stenting: Paucity of Late Clinical Stent-Related ProblemsJournal of the American College of Cardiology, 1996